PPSC and CeMOS form a strategic partnership
PPSC and CeMOS have formed a strategic partnership to provide industry-leading joint early drug discovery services, with an emphasis on label-free “cell-based” target-centric, phenotypic, and functional MALDI MS assays for ultra-High-Throughput Screening (uHTS), hit-to-lead biological profiling and in-vitro DMPK/ADME-T.
Preclinical Drug Discovery in just 5 days
After the success of last year, Radboud University has selected life sciences campus, Pivot Park in Oss, as the backdrop of one of their summer school courses in July 2022. Radboud University teamed up with Pivot Park Screening Centre, and HAN University of Applied Science to organize the summer school course: Introduction to preclinical drug discovery.
Sustainability at Pivot Park – replacement paper coffee cups
In 2020, we developed a strategic vision (Pivot Park Sustainability Report 2021-2026) of the opportunities and ambitions we can and could have regarding sustainability going forward. One of the short-term contributions we wanted to make is to replace the paper coffee cups.
Tienjarig bestaan van Pivot Park en het nieuwe Grizzly gebouw
Pivot Park viert deze week het tienjarig bestaan. Maar het mooiste ‘cadeau’ wordt pas in september 2023 uitgepakt: het grote gebouw Grizzly. Welke vijf bedrijven trekken daar in? Een voorstelrondje.
Synaffix Inks Deal with MacroGenics to Enable Next Generation ADCs
Synaffix announced their second deal of 2022 with MacroGenics, Inc. with a potential deal value of up to $586 million, plus royalties on commercial sales. MacroGenics will combine its proprietary antibody and bispecific DART® technology with their linker-payload technologies to develop up to three next generation both monospecific and bispecific conjugates.
Pivot Park viert tienjarig bestaan
De vlag kan uit op Pivot Park. Op 1 februari is het namelijk precies tien jaar geleden dat de Osse Life Sciences park zijn levenslicht zag. In die periode heeft het bedrijvenpark zich ontwikkeld tot een biofarmaceutische hotspot. Om het jubileum te vieren, staat Pivot Park in 2022 stil bij zijn successen en kijkt het uit naar de toekomst.
Genmab and Synaffix Sign ADC Technology Licensing Agreement
“We are very excited to advance our ambitions driving our valuable innovation-driven antibody discovery, selection, engineering, and manufacturing capabilities in our new state-of-the-art facility. We are confident that this expansion enables us to meet the growing interest in IPA’s custom antibody solutions and R&D activities.”
Pivot Park klaar voor de start van bouw Grizzly
Persbericht: Oss, 24 december Duurzaam life sciences-gebouw al grotendeels verhuurd Pivot Park klaar voor de start van bouw Grizzly Op
Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial
Citryll announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013. CIT-013 is a first in class humanized therapeutic antibody targeting Neutrophil Extracellular Trap (NET) formation and clearance.
Ardena has acquired Idifarma, a leading Contract Manufacturer of niche and highly potent generic and innovative drugs. The acquisition from SUANFARMA delivers expansion across Southern Europe and supports Ardena’s strategy to become a leading global CDMO, offering integrated solutions across the full pharma development lifecycle.
Let’s join PiVitality @ Pivot Park!
Pivot Park has vitality high on its agenda and offers several ways for community members to work on their vitality. That is why we have organised vitality-related events and also developed the PiVitality online program. With these activities, we hope you become more aware of your vitality, and as a consequence, and therefore more resilient. Are you curious about what Pivot Park is organising regarding vitality? Read it in our article.
Eerste studenten lectoraat Drug Discovery in september op Pivot Park
Het lectoraat Drug Discovery van de Academie Toegepaste Biowetenschappen en Chemie in Nijmegen start in september met zijn eerste studenten op het lab op Pivot Park. Het lectoraat maakt deel uit van de HAN University of Applied Sciences. We zitten in de kelder van het RE-gebouw (0201), een lab waar we zowel biologische als chemische onderwerpen kunnen adresseren en waar ongeveer 10 tot 15 studenten tegelijk kunnen werken.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.